<!DOCTYPE html>
<html lang="en-US"><head>
		<meta charset="UTF-8">
		<title>FR941116-2-00055</title>
	</head>
	<body>
		<main>
			<p><!-- PJG STAG 4703 -->  <!-- PJG ITAG l=69 g=1 f=1 -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=55 g=1 f=1 -->  <DOCTITLE>Prospective Grant of Partially Exclusive Patent License </DOCTITLE> <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <AGENCY> <!-- PJG ITAG l=10 g=1 f=2 --> AGENCY: <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 -->  National Institutes of Health, Public Health Service,  <!-- PJG 0012 frnewline --> DHHS.  <!-- PJG /ITAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->   <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> </AGENCY> <ACTION> <!-- PJG ITAG l=10 g=1 f=2 --> ACTION: <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 -->  Notice.  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=59 g=1 f=1 -->   <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG --> </ACTION> <SUMMARY> <!-- PJG ITAG l=10 g=1 f=2 --> SUMMARY: <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 -->  This is notice in accordance with 15 U.S.C. 209(c)(1)  <!-- PJG 0012 frnewline --> and 37 CFR 404.7(a)(1)(i) that the National Institutes of Health  <!-- PJG 0012 frnewline --> (NIH), Department of Health and Human Services, is contemplating  <!-- PJG 0012 frnewline --> the grant of a partially exclusive license in a limited field of  <!-- PJG 0012 frnewline --> use to practice the inventions embodied in U.S. Patent 5,104,977  <!-- PJG 0012 frnewline --> (formerly U.S. Patent Application 06/423,203) entitled ``Purified  <!-- PJG 0012 frnewline --> Transforming Growth Factor Beta'' and its foreign counterparts,  <!-- PJG 0012 frnewline --> including inventions deriving priority from U.S. Patent  <!-- PJG 0012 frnewline --> Applications 06/500,832 and 06/500,927, to Celtrix  <!-- PJG 0012 frnewline --> Pharmaceuticals Inc. having a place of business at Santa Clara,  <!-- PJG 0012 frnewline --> California. The patent rights in these inventions have been  <!-- PJG 0012 frnewline --> assigned to the United States of America.  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> The prospective partially exclusive license will be for the field  <!-- PJG 0012 frnewline --> of ophthalmology. It will be royalty-bearing and will comply  <!-- PJG 0012 frnewline --> with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7.  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> The prospective partially exclusive license may be granted  <!-- PJG 0012 frnewline --> unless, within sixty days from the date of this published Notice,  <!-- PJG 0012 frnewline --> NIH receives written evidence and argument that establishes that  <!-- PJG 0012 frnewline --> the grant of the license would not be consistent with the  <!-- PJG 0012 frnewline --> requirements of 35 U.S.C. 209 and 37 CFR 404.7.  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> This invention relates to a protein known as transforming growth  <!-- PJG 0012 frnewline --> factor-beta (TGF-beta) and its uses. The U.S. patent (5,104,977)  <!-- PJG 0012 frnewline --> issued on April 14, 1992 and has a divisional (USPA 07/816,563)  <!-- PJG 0012 frnewline --> and two continuations (08/048,956 and 08/267,227) currently  <!-- PJG 0012 frnewline --> pending at the U.S. PTO. The invention contains both composition  <!-- PJG 0012 frnewline --> of matter and method of using claims to TGF-beta. The invention  <!-- PJG 0012 frnewline --> facilitates studies relating TGF- <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=6 f=1 --> b <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> 's normal physiological  <!-- PJG 0012 frnewline --> function, and structural analysis, which could provide  <!-- PJG 0012 frnewline --> information on cloning of the TGF- <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=6 f=1 --> b <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  protein. Production of TGF- <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=6 f=1 --> b <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->   <!-- PJG 0012 frnewline --> in mass quantities might have useful therapeutic application in  <!-- PJG 0012 frnewline --> enhancement of wound healing and tissue repair. Requests for a  <!-- PJG 0012 frnewline --> copy of the above identified patent applications, inquiries,  <!-- PJG 0012 frnewline --> comments and other materials relating to the contemplated license  <!-- PJG 0012 frnewline --> should be directed to: Dr. Carl Floyd, Office of Technology  <!-- PJG 0012 frnewline --> Transfer, National Institutes of Health, 6011 Executive  <!-- PJG 0012 frnewline --> Boulevard, Box 13, Rockville, Maryland 20852&hyph;3804 (telephone:  <!-- PJG 0012 frnewline --> (301) 496&hyph;7735 ext. 246; FAX: (301) 402&hyph;0220). A signed  <!-- PJG 0012 frnewline --> Confidential Disclosure Agreement will be required to receive  <!-- PJG 0012 frnewline --> copies of the patent application(s). Properly filed competing  <!-- PJG 0012 frnewline --> applications for a license filed in response to this notice will  <!-- PJG 0012 frnewline --> be treated as objections to the grant of the contemplated  <!-- PJG 0012 frnewline --> license. Only written comments and/or applications for a license  <!-- PJG 0012 frnewline --> which are received by the NIH Office of Technology Transfer on or  <!-- PJG 0012 frnewline --> before January 17, 1995 will be considered.  <!-- PJG /ITAG -->  <!-- PJG QTAG 04 --> <!-- PJG /QTAG -->   <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG ITAG l=21 g=1 f=1 --> Dated: October 29, 1994. <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG --> </SUMMARY> <SIGNER> <!-- PJG ITAG l=06 g=1 f=1 --> Barbara M. McGarey,  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG --> </SIGNER> <SIGNJOB> <!-- PJG ITAG l=04 g=1 f=1 --> Deputy Director, Office of Technology Transfer.  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG --> </SIGNJOB> <FRFILING> <!-- PJG ITAG l=40 g=1 f=1 --> [FR Doc. 94&hyph;28302 Filed 11&hyph;15&hyph;94; 8:45 am] <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG --> </FRFILING> <BILLING> <!-- PJG ITAG l=68 g=1 f=1 --> BILLING CODE 4140&hyph;01&hyph;P <!-- PJG /ITAG --> </BILLING>  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /STAG --></p>
		</main>
</body></html>
            